Agreement

RNS Number : 8618G
Oxford Nanopore Technologies plc
01 April 2022
 

1 April 2022

Oxford Nanopore Technologies plc

Entry into settlement agreement with Department of Health and Social Care

The Department of Health and Social Care (DHSC) and Oxford Nanopore Technologies plc (ONT) reached an amicable resolution of the dispute relating to the contract dated 30 July 2020 for the supply of certain LamPORE™ devices and testing kits and associated services by ONT to DHSC. DHSC and ONT entered into a settlement agreement without any admission of liability, which included agreement as to the contract being brought to an end and includes a payment of £50 million in full of amounts due to ONT under the contract.

ONT expects the payment to be treated as non-recurring COVID-19 testing revenue during the fiscal year ended 31 December 2022. Therefore, ONT's prior guidance for Life Science Research Tools revenue in 2022 remains unchanged .

[ENDS]

Enquiries:

Investors

ir@nanoporetech.com  

Media

media@nanoporetech.com

oxfordnanoporetechnologies@tulchangroup.com

This announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU no. 596/2014), which forms part of English law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging the release of this announcement on behalf of the Company is Hannah Coote, Company Secretary of Oxford Nanopore Technologies plc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGREANDFDAAAEFA
UK 100

Latest directors dealings